Search Results - "Hassel, J.C."

Erythema nodosum-like lesions during BRAF inhibitor therapy: Report on 16 new cases and review of the literature by Mössner, R., Zimmer, L., Berking, C., Hoeller, C., Loquai, C., Richtig, E., Kähler, K.C., Hassel, J.C., Gutzmer, R., Ugurel, S.

“…Importance BRAF inhibitors have been licensed for the therapy of BRAF‐mutated melanoma. Recently, inflammatory skin lesions clinically resembling erythema…”
Get full text

Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion by Potthoff, K., Hofheinz, R., Hassel, J.C., Volkenandt, M., Lordick, F., Hartmann, J.T., Karthaus, M., Riess, H., Lipp, H.P., Hauschild, A., Trarbach, T., Wollenberg, A.

“…Anti-epidermal growth factor receptor treatment strategies, i.e. monoclonal antibodies such as cetuximab and panitumumab, or epidermal growth factor receptor…”
Get full text

Anti-programmed cell death-1 therapy in nonmelanoma skin cancer by Winkler, J K, Schneiderbauer, R, Bender, C, Sedlaczek, O, Fröhling, S, Penzel, R, Enk, A, Hassel, J C

Get full text

3310 LOGIC2: Phase 2, multi-center, open-label study of sequential encorafenib/binimetinib combination followed by a rational combination with targeted agents after progression, to overcome resistance in adult patients with locally-advanced or metastatic BRAF V600 melanoma by Dummer, R, Sandhu, S, Hassel, J.C, Muñoz, E, Berking, C, Gesierich, A, Ascierto, P.A, Esposito, O, Carter, K, Antona, V, Radhakrishnan, R, Cui, X, Caponigro, G, Jaeger, S, Demuth, T, Miller Jr, W.H

Get full text

3303 Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients with advanced melanoma (MEL) (CheckMate 067) by Larkin, J, Chiarion-Sileni, V, Gonzalez, R, Grob, J.J, Cowey, C.L, Lao, C.D, Wagstaff, J, Hogg, D, Hill, A, Carlino, M.S, Wolter, P, Lebbé, C, Schachter, J, Thomas, L, Hassel, J.C, Lorigan, P, Walker, D, Jiang, J, Hodi, F.S, Wolchok, J.D

Get full text

Corrigendum to ‘IgE blockade in the management of eosinophil-associated recalcitrant pruritus due to medical tumor therapy’ by Gutzmer, R., Sibaud, V., Hassel, J.C.

Get full text

Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab by Menzies, A.M., Johnson, D.B., Ramanujam, S., Atkinson, V.G., Wong, A.N.M., Park, J.J., McQuade, J.L., Shoushtari, A.N., Tsai, K.K., Eroglu, Z., Klein, O., Hassel, J.C., Sosman, J.A., Guminski, A., Sullivan, R.J., Ribas, A., Carlino, M.S., Davies, M.A., Sandhu, S.K., Long, G.V.

“…Anti-PD-1 antibodies (anti-PD-1) have clinical activity in a number of malignancies. All clinical trials have excluded patients with significant preexisting…”
Get full text

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy by Eggermont, Alexander M.M, Chiarion-Sileni, Vanna, Grob, Jean-Jacques, Dummer, Reinhard, Wolchok, Jedd D, Schmidt, Henrik, Hamid, Omid, Robert, Caroline, Ascierto, Paolo A, Richards, Jon M, Lebbé, Céleste, Ferraresi, Virginia, Smylie, Michael, Weber, Jeffrey S, Maio, Michele, Bastholt, Lars, Mortier, Laurent, Thomas, Luc, Tahir, Saad, Hauschild, Axel, Hassel, Jessica C, Hodi, F. Stephen, Taitt, Corina, de Pril, Veerle, de Schaetzen, Gaetan, Suciu, Stefan, Testori, Alessandro

“…Patients with surgically resected stage III melanoma are at high risk for recurrence. The 5-year survival rate with ipulimumab was 11 percentage points higher…”
Get full text

IgE blockade in the management of eosinophil-associated recalcitrant pruritus due to medical tumor therapy by Gutzmer, R., Sibaud, V., Hassel, J.C.

Get full text

Corrigendum to ‘IgE blockade in the management of eosinophil-associated recalcitrant pruritus due to medical tumor therapy’: Annals of Oncology 2021; volume 32: 696-697 by Gutzmer, R., Sibaud, V., Hassel, J.C.

Get full text

1126P Prediction of clinical outcome by soluble immune checkpoints and T cell subsets in patients treated with immune checkpoint blockers for metastasized melanoma by Hassel, J.C., Wiecken, M., Hülsmeyer, I., Roth, J., Eurich, R., Machiraju, D.

Get full text

1809O TRheuMa registry provides real world data on rheumatic immune-related adverse events by Benesova, K., Diekmann, L., Lorenz, H-M., Leipe, J., Kunz, J., Hassel, J.C., Jordan, K.

Get full text

Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study by Long, G.V., Atkinson, V., Ascierto, P.A., Robert, C., Hassel, J.C., Rutkowski, P., Savage, K.J., Taylor, F., Coon, C., Gilloteau, I., Dastani, H.B., Waxman, I.M., Abernethy, A.P.

“…Nivolumab has shown significant survival benefit and a favorable safety profile compared with dacarbazine chemotherapy among treatment-naïve patients with…”
Get full text

1087MO A single arm phase II, multicenter trial to evaluate the clinical activity and safety of avelumab plus cetuximab in unresectable stage III or IV cutaneous squamous cell carcinoma: First results from the AliCe study by Becker, J.C., Schilling, B., Leiter-Stoppke, U., Zimmer, L., Hassel, J.C., von Wasielewski, I., Ziemer, M., Fluck, M., Meier, F., Spillner, A., Gesierich, A., Eigentler, T., Livingstone, E., Albers, M., Angela, Y., Gutzmer, R.

Get full text

1037P Phase I dose-escalation trial with tumor-targeted interleukin-12 (IL12-L19L19) in patients with solid tumors by Mach, N., Belli, C., Fernandez, E., Alsdorf, W., Colombo, I., Dakhel, S., Hemmerle, T., Puca, E., Libbra, C., Mulatto, S., Mock, J.C., Lorizzo, K., Neri, D., Covelli, A., Lauer, U., Hassel, J.C., Stathis, A., Fiedler, W.M., Curigliano, G.

Get full text

1107P BRAF mutation status does not impact outcomes with tebentafusp in advanced cutaneous melanoma by Shoushtari, A.N., Middleton, M.R., Hamid, O., Meier, F., Bauer, T., Salama, A.K.S., Kirkwood, J.M., Ascierto, P.A., Lorigan, P., Mauch, C., Orloff, M., Edukulla, R., Goodall, H., Hassel, J.C., Evans, T.R.J.

Get full text

Acral lentiginous melanoma: a skin cancer with unfavourable prognostic features. A study of the German central malignant melanoma registry (CMMR) in 2050 patients by Teramoto, Y., Keim, U., Gesierich, A., Schuler, G., Fiedler, E., Tüting, T., Ulrich, C., Wollina, U., Hassel, J.C., Gutzmer, R., Goerdt, S., Zouboulis, C., Leiter, U., Eigentler, T.K., Garbe, C.

“…Summary Background Acral lentiginous melanoma (ALM) is one of the four major subtypes in cutaneous melanoma (CM). Although ALM has a poorer prognosis than…”
Get full text

Safety of the PD-1 antibody pembrolizumab in patients with high-grade adverse events under ipilimumab treatment††Note on previous publication of this work: Part of this work was presented as poster presentation at the 25. Deutscher Hautkrebskongress (25. German Skin Cancer Congress), 10–12 September 2015 in Munich, Germany. The abstract was published in the online portal of JDDG. See ref. [1] by Bender, C., Dimitrakopoulou-Strauss, A., Enk, A., Hassel, J.C.

Get full text

832P Treatment sequence with tebentafusp (tebe) and anti-PD1/ipilimumab (PD1+IPI) in HLA-A202:01 patients (pts) with metastatic uveal melanoma (mUM) by Dimitriou, F., Hassel, J.C., Orloff, M., Hughes, I., Kapiteijn, E., Mehmi, I., Montazeri, K., Johnson, D.B., Grover, P., Gerard, C.L., Simeone, E., Gaudy Marqueste, C., Cheng, P., Long, G.V., Carvajal, R.D., Dummer, R.

Get full text

823P A propensity score weighted comparison of tebentafusp or pembrolizumab versus combination ipilimumab and nivolumab in untreated metastatic uveal melanoma by Piulats Rodriguez, J.M., Piperno-Neumann, S., Rutkowski, P., Nathan, P., Hassel, J.C., Espinosa, E., de la Cruz Merino, L., Ochsenreither, S., Shoushtari, A.N., Orloff, M., Salama, A.K.S., Watkins, C., Goodall, H., Baurain, J-F.

Get full text